Please assess the completion status of the following clinical trial:

Trial Title: Different Doses of Roxadustat Treatment for Anemia in Peritoneal Dialysis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients diagnosed with Chronic kidney disease stage 5~2. Maintenance on PD for more than three months.~3. Weight between 45Kg and 110Kg~4. Renal anemia, and hemoglobin between 90g/L and 120g/L~5. Stop taking erythropoietin for enough time （erythropoietin treatment discontinuation for ≥3 days if using erythropoietin of 3000U single strength, or ≥7 days if using erythropoietin of 10000U single strength） or free of erythropoietin use~6. Signed the informed consent.~7. Willing to follow the study procedure~Exclusion Criteria:~1. Hematologic malignancy or aplastic anemia.~2. Blood loss or hemolysis.~3. Taking roxadustat, or Allergy or intolerance to roxadustat~4. Severe liver injury or active hepatitis.~5. Pregnancy or breastfeeding~6. Cancer, receiving radiotherapy and chemotherapy within 6 months.~7. Refractory hypertension

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- standard roxadustat dosage group (Type: EXPERIMENTAL): Peritoneal dialysis patients diagnosed with renal anemia will receive standard dosage of roxadustat according to weight.
- lower roxadustat dosage group (Type: EXPERIMENTAL): Peritoneal dialysis patients diagnosed with renal anemia will receive lower dosage of roxadustat according to weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).